Loading briefing details...
Loading briefing details...
News Briefs
By: Brief The Press
Category:Business,Health,Science & Environment
May 28, 2026
This expansion by Creative BioMart significantly enhances the development of more accurate and diverse in vitro diagnostic tests. By offering a broader range of high-quality diagnostic antibodies and customization, it accelerates research and commercialization of critical assays, leading to earlier and more precise disease detection, ultimately improving patient outcomes globally.
Creative BioMart, a leading biotech supplier, has significantly expanded its portfolio of diagnostic antibody products to advance precision in vitro diagnostic (IVD) assay development. These high-quality antibodies are crucial for the screening, detection, and accurate diagnosis of a broad range of conditions, including tumors, cardiovascular diseases, inflammation, and infectious diseases. As a fundamental component in modern diagnostic kits, these antibodies are integral to technologies such as ELISA, chemiluminescence, and immunoturbidimetric assays.
The enhanced product line now offers a broader selection of IVD-grade diagnostic antibodies sourced from diverse species like human, sheep, mouse, and rabbit. This variety, alongside different production systems, provides greater flexibility for antibody pairing and optimizes assay formats. Creative BioMart also emphasizes its customization services, enabling partners to develop exclusive diagnostic antibodies tailored to specific research needs.
This strategic expansion reinforces Creative BioMart's dedication to empowering diagnostic innovation. The company offers an extensive array of related products, including tumor markers, IVD components for autoimmune and metabolic conditions, and various diagnostic antigens. With a robust history in protein development and a vast catalog, Creative BioMart continues to be a trusted partner, driving progress in the global diagnostic field.